Capmatinib dihydrochloride hydrate

In Vitro Capmatinib (INCB28060) inhibits c-MET phosphorylation with an IC 50 value of approximately 1 nM and a concentration of approximately 4 nM inhibits c-MET more than 90%, which is reversible and the effect is significantly reduced in several hours after the compound is removed and completely disappeared by 48 hours. Capmatinib (INCB28060) (0-10000 nM; 72 h) inhibits the proliferation of SNU-5, S114, H441 and U-87MG. Capmatinib (INCB28060) (0.06-62.25 nM; 2h) effectively inhibits phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib (INCB28060) (0.24-63 nM; over night) prevents HGF-stimulated H441 cell migration. Capmatinib (INCB28060) (0.5-50 nM; 20 min) suppresses phosphorylation of both EGFR and HER-3 rapidly. Capmatinib (INCB28060) (0-333 nM; 24 h) induces apoptosis in SNU-5 cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: SNU-5, S114, H441 and U-87MG Concentration: 0-10000 nM Incubation Time: 72 h Result: Inhibited the cell viability of SNU-5 and S114, as well as the colony formation of H441 and U-87MG, with IC 50 values of 1.2 nM, 12.4 nM, ~0.5 nM and 2 nM, respectively. Cell Migration AssayCell Line: H441 (stimulated with 50 ng/mL recombinant human HGF for 24h) Concentration: 0.24, 1, 4, 16 and 63 nM Incubation Time: Over night Result: Prevented HGF-stimulated H441 cell migration, with IC 50 of approximately 2 nM, and less cell migration at 16 nM. Western Blot AnalysisCell Line: SNU-5 Concentration: 0.06, 0.24, 0.98, 3.91, 15.63 and 62.25 nM Incubation Time: 2 h Result: Effectively inhibited phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Western Blot AnalysisCell Line: H1993 cells Concentration: 0.5, 5 and 50 nM Incubation Time: 20 min Result: Suppressed phosphorylation of both EGFR and HER-3 rapidly and as effectively as the compound inhibited c-MET phosphorylation in H1993 cells. Apoptosis AnalysisCell Line: SNU-5 cells Concentration: 0.017, 0.15, 1.37, 12.33, 111 and 333 nM Incubation Time: 24 h Result: Effectively induced DNA fragmentation. In Vivo Capmatinib (INCB28060) (1-30 mg/kg; PO, twice daily, for 2 weeks) exhibits dose-dependent inhibition of tumor growth, and shows well tolerance at all doses during the treatment periods, with no evidence of overt toxicity or weight loss in U-87MG tumor mice model . Capmatinib (INCB28060) (0.03-10 mg/kg; PO, single dosage) causes inhibition of c-MET phosphorylation in S114 tumor mice model . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Female Balb/c nu/nu mice (inoculated subcutaneously with 5×10 6 U-87MG glioblastoma cells) Dosage: 1, 3, 10 and 30 mg/kg Administration: PO, twice daily, for 2 weeks Result: Exhibited dose-dependent inhibition of tumor growth with 35% and 76% at 1 and 3 mg/kg once daily; resulted in partial regressions in 6 of 10 U-87MG tumor-bearing mice at 10 mg/kg once daily; and showed well tolerance at all doses during the treatment periods, with no evidence of overt toxicity or weight loss. Animal Model: Female Balb/c nu/nu mice (inoculated subcutaneously with 4×10 6 S114 tumor cells) Dosage: 0.03, 0.1, 0.3, 1, 3 and 10 mg/kg Administration: PO, single dosage Result: Caused approximately 50% and 90% inhibition of c-MET phosphorylation at 0.03 and 0.3 mg/kg after administration of 30 min, and inhibition of phospho-c-MET exceeded 90% after 7 hours. Form:Solid

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet